Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer

被引:20
作者
Boevee, S. J. [1 ]
Venderbos, L. D. F. [1 ]
Tammela, T. L. J. [2 ]
Nelen, V. [3 ]
Ciatto, S. [4 ]
Kwiatkowski, M. [5 ]
Paez, A. [6 ]
Malavaud, B. [7 ]
Hugosson, J. [8 ]
Roobol, M. J. [1 ]
机构
[1] Univ Med Ctr, Erasmus MC, Dept Urol, NL-3000 CA Rotterdam, Netherlands
[2] Tampere Univ, Div Urol, FIN-33101 Tampere, Finland
[3] Prov Inst Hyg, Antwerp, Belgium
[4] Ctr Studio & Prevenz Oncol, Florence, Italy
[5] Kantonsspital Aarau, Urol Clin, Aarau, Switzerland
[6] Univ Hosp Getafe, Madrid, Spain
[7] CHU Rangueil, Dept Urol, F-31054 Toulouse, France
[8] Sahlgrens Univ Hosp, Dept Urol, S-41345 Gothenburg, Sweden
关键词
Prostate cancer; Prognostic factors; Screening; Screen versus control arm; Treatment; Stage; Grade; Randomised trial; TRIAL; ROTTERDAM; SECTION; ERSPC; CONTAMINATION; FEATURES; ROUNDS; RISK;
D O I
10.1016/j.ejca.2010.09.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate a change in tumour characteristics and applied treatments over time in the control arm of all centres of the European Randomized study of Screening for Prostate Cancer (ERSPC) and to compare this with similar data of the screening arm. Methods: Between 1993 and 2003, 182,160 men, aged 50-74 years, were randomised to the screening arm (N = 82,816) and the control arm (N = 99,184). Men in the screening arm were offered Prostate Specific Antigen (PSA) testing every 4 years whilst men in the control arm received usual care. Tumour characteristics and treatment were evaluated in all men diagnosed with prostate cancer up to December 2006 or the third screening round. Data on the control arm were divided into 3 periods: 1994-1998, 1999-2002 and 2003-2006. Results: Tumour characteristics were more favourable over time in both the control and the screening arm, with especially increasing proportions of T1C tumours with 29% in 19941998 versus 50% in 2003-2006 and 48% at the initial screening round versus 75% at the third screening round, respectively. Tumour characteristics observed in the last period of the control arm were comparable to tumour characteristics in the initial screening round. In the control arm, treatment changed over time with surgery as the most common treatment in the entire observed period, but almost doubling of expectant management and the combination of hormone therapy and radiotherapy over time. In the initial screening round, surgery was the most common treatment (42%), changing over time to expectant management as the most frequently applied treatment in the third screening round (33%). Conclusion: Tumour characteristics in the control arm became more favourable over time and show similarity with prostate cancer cases detected at the initial screening round. The most prominent change in treatment over time was an increase of application of expectant management in both arms of the ERSPC. These observations reflect an increasing rate of opportunistic testing over time in men randomised to the control arm. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3082 / 3089
页数:8
相关论文
共 21 条
[1]   Prostate cancer and the Will Rogers phenomenon [J].
Albertsen, PC ;
Hanley, JA ;
Barrows, GH ;
Penson, DF ;
Kowalczyk, PDH ;
Sanders, MM ;
Fine, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) :1248-1253
[2]   Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - Results from a prospective, population-based randomized controlled trial [J].
Aus, Gunnar ;
Bergdahl, Suante ;
Lodding, Par ;
Liija, Hans ;
Hugosson, Jonas .
EUROPEAN UROLOGY, 2007, 51 (03) :659-664
[3]   Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer:: European randomized study of screening for prostate cancer, Rotterdam [J].
Beemsterboer, PMM ;
de Koning, HJ ;
Kranse, R ;
Trienekens, PH ;
van der Maas, PJ ;
Schröder, FH .
JOURNAL OF UROLOGY, 2000, 164 (04) :1216-1220
[4]   Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer [J].
Bolla, M .
EUROPEAN UROLOGY, 1999, 35 :23-25
[5]   Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening [J].
Ciatto, S ;
Zappa, M ;
Villers, A ;
Paez, A ;
Otto, S ;
Auvinen, A .
BJU INTERNATIONAL, 2003, 92 :97-100
[6]   Management of localized prostate cancer in men over 65 years [J].
Cooperberg, Matthew R. ;
Konety, Badrinath R. .
CURRENT OPINION IN UROLOGY, 2009, 19 (03) :309-314
[7]   The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management [J].
Cooperberg, MR ;
Lubeck, DP ;
Meni, MV ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2141-2149
[8]   Prostate cancer: Trends in incidence, survival and mortality in the Netherlands, 1989-2006 [J].
Cremers, R. G. H. M. ;
Karim-Kos, H. E. ;
Houterman, S. ;
Verhoeven, R. H. A. ;
Schroder, F. H. ;
van der Kwast, T. H. ;
Kil, P. J. M. ;
Coebergh, J. W. W. ;
Kiemeney, L. A. L. M. .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) :2077-2087
[9]   Gleason score, age and screening:: Modeling dedifferentiation in prostate cancer [J].
Draisma, Gerrit ;
Postma, Renske ;
Schroder, Fritz H. ;
van der Kwast, Theo H. ;
de Koning, Harry J. .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (10) :2366-2371
[10]   Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma [J].
Hugosson, J ;
Aus, G ;
Lilja, H ;
Lodding, P ;
Pihl, CG .
CANCER, 2004, 100 (07) :1397-1405